Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/11050
SEOM Clinical guidelines for the treatment of metastatic prostate cancer
Identifiers
ISSN: 1699-048X
eISSN: 1699-3055
WOS ID: 000345397300006
Scopus EID: 2-s2.0-84919419308
PMID: 25319721
Embase PUI: L600179806
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordPublication date
2014-12Document type
research articleCitation
Cassinello J, Climent MA, Gonzalez Del Alba A, Mellado B, Virizuela JA. SEOM Clinical guidelines for the treatment of metastatic prostate cancer. Clin Transl Oncol. 2014 Dec;16(12):1060-6. Epub 2014 Oct 16.Abstract
Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptomatic metastatic castration-resistant prostate cancer (CRPC), three treatment virtual spaces, for treatment and drug development in CPRC, have emerged: pre-docetaxel, docetaxel combinations and post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years. Patients are now living longer and experiencing better quality of life. Strategies for patient selection and treatment sequencing are therefore urgently required.
Publisher version
https://dx.doi.org/10.1007/s12094-014-1225-3Keywords
Androgen deprivation treatmentCastration-resistant prostate cancer
Docetaxel
Cabacitaxel
Abiraterone
Enzalutamide
Radium 223
This item appears in following Docusalut collections
Hospital Universitario Son Espases - HUSE > Comunicación científicaInstituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica